GlassScriptPhysician profile
Del Charbonier
NPI 1821198003
$2,273.04
in general payments reported to CMS, 2019-2025
31 companies · $58.75 in 2025
The $58.75 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $509 · 2021: $739 · 2022: $506 · 2023: $66.64 · 2024: $19.02 · 2025: $58.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $144.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $347.21 | 2020-2023 | Emgality, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.96 | 2019-2022 | |
| Abbvie INC. | $286.53 | 2021-2023 | Vraylar |
| Astellas Pharma US INC | $236.80 | 2019-2022 | |
| Pfizer INC. | $194.93 | 2019-2022 | |
| Glaxosmithkline, LLC. | $128.08 | 2020-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $81.88 | 2019-2020 | |
| Bausch Health US, LLC | $69.55 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $64.54 | 2021-2022 | |
| Exact Sciences Corporation | $58.75 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $51.86 | 2019-2020 | |
| Vivus LLC | $51.84 | 2022 | |
| Radius Health, INC. | $36.28 | 2019-2020 | |
| Almatica Pharma LLC | $32.72 | 2021-2022 | |
| Allergan, INC. | $31.08 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $29.50 | 2022 | |
| Boston Scientific Corporation | $28.76 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $26.68 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.16 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.02 | 2024 | Lifevest |
| Eisai INC. | $18.23 | 2020 | |
| Phadia US INC. | $17.38 | 2019 | |
| Amgen INC. | $17.24 | 2022 | |
| Axonics, INC. | $16.73 | 2022 | |
| Esperion Therapeutics, INC. | $15.31 | 2020 | |
| Bardy Diagnostics, INC. | $14.85 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.43 | 2021 | |
| Ibsa Pharma INC. | $14.39 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.24 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.78 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Del Charbonier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.